论文部分内容阅读
目的探讨尿激酶静脉溶栓治疗急性脑梗死的疗效。方法对发病 12小时内的 2 0 0例急性脑梗死患者 ,随机分溶栓组和丹参等常规治疗组 ,溶栓组尿激酶剂量为 10 0～ 15 0 U,静脉滴注。结果基本痊愈率为 6 0 .0 % ( 6 3/10 5 ) ,总显效率为 88.6 % ( 93/10 5 ) ,病死率为2 .9% ( 3/10 5 ) ,脑内出血性并发症为 8.6 % ( 9/10 5 ) ,常规治疗组基本痊愈率为 6 .3% ( 11/95 ) ,总显效率为 35 .8% ( 34/95 ) ,病死率为11.6 % ( 11/95 ) ,脑内出血性并发症为 1.1% ( 1/95 )。结论溶栓组疗效显著高于常规治疗组 ( P<0 .0 5 ) ,但脑出血并发症也显著高于常规治疗组 ( P<0 .0 1)
Objective To investigate the curative effect of intravenous thrombolytic therapy of urokinase on acute cerebral infarction. Methods A total of 200 patients with acute cerebral infarction within 12 hours after onset were randomly divided into the thrombolytic group and the conventional treatment group. The dose of urokinase in the thrombolytic group was 100-1500 U. Results The basic cure rate was 60.0% (63/105), the total effective rate was 88.6% (93/105), the mortality rate was 2.9% (3/105), intracerebral hemorrhagic complications (8.6%), the basic cure rate was 6.3% (11/95) in the conventional treatment group, the overall effective rate was 35.8% (34/95) and the case fatality rate was 11.6% (11/95) ), Intracerebral hemorrhagic complications were 1.1% (1/95). Conclusion The curative effect of thrombolytic group is significantly higher than that of conventional treatment group (P <0.05), but the complication of intracerebral hemorrhage is also significantly higher than that of routine treatment group (P <0.01)